|Leave a Message or Start an on-line Chat
The production of the BCL2 recombinant monoclonal antibody involves the utilization of protein technology and DNA recombinant techniques. In this process, animals are initially immunized with a synthesized peptide derived from human BCL2, and B cells are extracted from the immunized mice. From these B cells, positive ones are isolated and subjected to single clone identification. The genes responsible for the light and heavy chains of the BCL2 antibody are then amplified using PCR and incorporated into a plasmid vector. This recombinant vector is subsequently introduced into host cells for antibody expression. Through affinity chromatography, the BCL2 recombinant monoclonal antibody is purified from the supernatant of the cell culture. Rigorous validation ensures the reliability and applicability of the antibody in various experimental techniques, including ELISA, WB, IHC, and FC. This antibody is designed to specifically target the Bcl-2 protein in human, mouse, and rat species.
Applications : Immunohistochemical staining
Sample type: tissue
Review: Effects of n3-PUFAs (n-3, 300 mg/kg) and metformin (Met, 150 mg/kg) on relative hepatic tissue expression of peroxisome proliferator-activated receptor alpha (PPAR-α) and B-cell lymphoma 2 (Bcl-2) in high-fat diet/low dose streptozotocin (HFD-STZ)-induced NAFLD in rats by immunohistochemistry. (×400, scale bar = 50um).